Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Tirzepatide, available as Mounjaro and Zepbound, contain both GLP-1 and GIP receptor agonists
Providers are encouraged to exercise their own clinical judgment based on each individual patients health care needs.
can help ensure value for money and better sourcing decisions
Several candidates are advancing through clinical development, including orforglipron, currently in Phase III trials for obesity and type 2 diabetes
Product Specifications Research Overview This page covers the 30mg presentation of Retatrutide, the largest vial content stocked
[2] Since then, several other GLP-1 agonists have been developed and approved for clinical use, including liraglutide (Victoza), dulaglutide (Trulicity), semaglutide (Ozempic and Wegovy), and Tirzepatide (Mounjaro and Zepbound)
